相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.
Luis Villanueva et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
Hyehyun Jeong et al.
CANCERS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
Xiaofen Li et al.
ONCOTARGETS AND THERAPY (2021)
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
Stephen P. Hack et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma
Yeseul Kim et al.
CANCER RESEARCH AND TREATMENT (2020)
The world-wide incidence of biliary tract cancer (BTC).
Huifen Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation
Wei Zhang et al.
ONCOLOGIST (2020)
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer
Richard D. Kim et al.
EUROPEAN JOURNAL OF CANCER (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
Qing-Hai Li et al.
GASTROENTEROLOGY REPORT (2020)
Molecular profile of BRCA-mutated biliary tract cancers
Gilbert Spizzo et al.
ESMO OPEN (2020)
DNA damage repair response in mesenchymal stromal cells: From cellular senescence and aging to apoptosis and differentiation ability
Behnaz Banimohamad-shotorbani et al.
AGEING RESEARCH REVIEWS (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
Makoto Ueno et al.
BMC CANCER (2020)
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer
Reham Abdel-Wahab et al.
SCIENTIFIC REPORTS (2020)
A review of cancer immunotherapy: from the past, to the present, to the future
K. Esfahani et al.
CURRENT ONCOLOGY (2020)
Overview of current targeted therapy in gallbladder cancer
Xiaoling Song et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
Ji Hye Kim et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2020)
Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis
Alessandro Rizzo et al.
IN VIVO (2020)
Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
Maolan Li et al.
GUT (2019)
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
S. T. Kim et al.
ANNALS OF ONCOLOGY (2019)
Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
Tatsuya Ioka et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
Aaron C. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.
Masafumi Ikeda et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo
Wei Wang et al.
BIOMED RESEARCH INTERNATIONAL (2019)
A phase II study of anti PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
O-005Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial
J Harding et al.
ANNALS OF ONCOLOGY (2019)
Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study
Jin Won Kim et al.
BRITISH JOURNAL OF CANCER (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
C. Morizane et al.
ANNALS OF ONCOLOGY (2019)
A Phase 2 Trial of Regorafenib as a Single Agent in Patients With Chemotherapy-Refractory, Advanced, and Metastatic Biliary Tract Adenocarcinoma
Weijing Sun et al.
CANCER (2019)
Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
Francesca Corti et al.
CANCER TREATMENT REVIEWS (2019)
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study
Jean-Marc Phelip et al.
DIGESTIVE AND LIVER DISEASE (2019)
Modified gemcitabine and oxaliplatin or gemcitabine plus cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial
Atul Sharma et al.
EUROPEAN JOURNAL OF CANCER (2019)
Contemporary Tailored Oncology Treatment of Biliary Tract Cancers
Fiona Turkes et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2019)
Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients
Pingzhou Yang et al.
HEPATOBILIARY SURGERY AND NUTRITION (2019)
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers
Kabir Mody et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Overview of current systemic management of EGFR-mutant NSCLC
W. -H. Hsu et al.
ANNALS OF ONCOLOGY (2018)
Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy
Azfar Neyaz et al.
HISTOPATHOLOGY (2018)
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik-Tobias Arkenau et al.
ONCOLOGIST (2018)
EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs
Wen Cai et al.
JOURNAL OF CANCER (2018)
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression
Jianzhen Lin et al.
BMC CANCER (2018)
Serum vascular endothelial growth factor-C levels predict lymph node metastasis and prognosis of patients with gallbladder cancer
Lei Jiang et al.
ONCOLOGY LETTERS (2018)
615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)
D Sakai et al.
ANNALS OF ONCOLOGY (2018)
New developments in systemic therapy for advanced biliary tract cancer
Chigusa Morizane et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
Masafumi Ikeda et al.
CANCER SCIENCE (2018)
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
Loic Verlingue et al.
EUROPEAN JOURNAL OF CANCER (2017)
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option
Valeria Simone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Pertuzumab plus trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.
Milind M. Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Global epidemiological trends and variations in the burden of gallbladder cancer
Chandrakanth Are et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma
Wen-Chih Huang et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2017)
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Talia Golan et al.
ONCOLOGIST (2017)
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle et al.
CANCER DISCOVERY (2017)
Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
J. Bridgewater et al.
ANNALS OF ONCOLOGY (2016)
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
Francesco Leone et al.
CANCER (2016)
Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management
Milind Javle et al.
CANCER (2016)
Molecular characteristics of biliary tract cancer
Davendra P. S. Sohal et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Response of BRCA1- mutated gallbladder cancer to olaparib: A case report
Yuan Xie et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
Hyerim Ha et al.
ONCOTARGET (2016)
KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers
Masaaki Yokoyama et al.
JAPANESE CLINICAL MEDICINE (2016)
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
J. S. Chen et al.
ANNALS OF ONCOLOGY (2015)
Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer
M. Zuo et al.
BRITISH JOURNAL OF CANCER (2015)
HER2 expression status in diverse cancers: review of results from 37,992 patients
Min Yan et al.
CANCER AND METASTASIS REVIEWS (2015)
SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway
Yi-Jun Shu et al.
MOLECULAR CANCER (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
Daniel H. Ahn et al.
SCIENTIFIC REPORTS (2015)
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
A. Santoro et al.
ANNALS OF ONCOLOGY (2015)
Gemcitabine (G), capecitabine (C) and bevacizumab (BV) in patients with advanced biliary cancers (ABC): final results of a multicenter phase II study.
Renuka V. Iyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized phase II crossover trial exploring the clinical benefit from targeting EGFR or VEGF with combination chemotherapy in patients with non-resectable biliary tract cancer.
Lars Henrik Jensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study
R. Buzzoni et al.
ANNALS OF ONCOLOGY (2014)
A genetic model for gallbladder carcinogenesis and its dissemination
S. G. Barreto et al.
ANNALS OF ONCOLOGY (2014)
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
A. F. Hezel et al.
BRITISH JOURNAL OF CANCER (2014)
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
A. B. El-Khoueiry et al.
BRITISH JOURNAL OF CANCER (2014)
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
L. Fornaro et al.
BRITISH JOURNAL OF CANCER (2014)
Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer
Shojiro Matsushita et al.
CANCER SCIENCE (2014)
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors
Brian A. Costello et al.
INVESTIGATIONAL NEW DRUGS (2014)
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
Benjamin Goeppert et al.
MODERN PATHOLOGY (2014)
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka et al.
LANCET ONCOLOGY (2014)
Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway
Maolan Li et al.
NATURE GENETICS (2014)
Role of aberrant PI3K pathway activation in gallbladder tumorigenesis
Andrea Lunardi et al.
ONCOTARGET (2014)
Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.
Yvonne H. Yeung et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Immunohistochemical Expression of Phospho-mTOR Is Associated With Poor Prognosis in Patients With Gallbladder Adenocarcinoma
Pamela Leal et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2013)
Vascular endothelial growth factor single-nucleotide polymorphism in gall bladder cancer
Kumudesh Mishra et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
L. H. Jensen et al.
ANNALS OF ONCOLOGY (2012)
A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
Jun Ho Yi et al.
EUROPEAN JOURNAL OF CANCER (2012)
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
Jeeyun Lee et al.
LANCET ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunohistochemical evidence of the prognostic value of hedgehog pathway components in primary gallbladder carcinoma
Jinmao Li et al.
SURGERY TODAY (2012)
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Vikram Deshpande et al.
BMC CANCER (2011)
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Tanios Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma
Xiao-Nan Sun et al.
TUMOR BIOLOGY (2011)
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
Ymera Pignochino et al.
BMC CANCER (2010)
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
Aram F. Hezel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
Birgit Gruenberger et al.
LANCET ONCOLOGY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K. Ramanathan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
F. Eckel et al.
BRITISH JOURNAL OF CANCER (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The hedgehog signaling pathway in cancer
Marie Evangelista et al.
CLINICAL CANCER RESEARCH (2006)
Phase II study of erlotinib in patients with advanced biliary cancer
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
AX Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers
K Nakazawa et al.
JOURNAL OF PATHOLOGY (2005)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
